Related Experiment Videos

Plasma homocyst(e)ine as a risk factor for early familial coronary artery disease

L L Wu1, J Wu, S C Hunt

  • 1Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City 84132.

Clinical Chemistry
|April 1, 1994
PubMed

Insights

Elevated plasma homocysteine (H(e)) is linked to early familial coronary artery disease. Genetic factors likely contribute to high H(e) levels, increasing heart disease risk in affected families.

Area of Science:

  • Cardiovascular Genetics
  • Metabolic Disorders
  • Biochemistry

Background:

  • Early-onset coronary artery disease (CAD) often has a familial component.
  • Elevated plasma homocysteine (H(e)) is a known risk factor for cardiovascular disease.
  • The genetic basis for familial hyperhomocysteinemia in early CAD requires further elucidation.

Purpose of the Study:

  • To investigate the association between plasma homocysteine (H(e)) levels and early-onset familial coronary artery disease.
  • To determine if genetic factors contribute to elevated H(e) in families with multiple affected siblings.
  • To identify H(e) as a potential biomarker for genetic predisposition to early CAD.

Main Methods:

  • Cross-sectional study comparing plasma H(e) in patients with early CAD and controls.
  • Analysis of H(e) concentrations adjusted for covariates like serum creatinine, uric acid, and LDL cholesterol.
  • Examination of H(e) distribution and familial aggregation in affected families.

Main Results:

  • Proband cases with early CAD exhibited significantly higher adjusted mean H(e) (12.0 mumol/L) compared to controls (10.1 mumol/L).
  • 17.6% of proband cases had H(e) levels above the 95th percentile of controls, indicating a substantial risk.
  • Bimodal distribution of H(e) in cases and concordant high H(e) in 12% of families suggest a major gene effect.

Conclusions:

  • Elevated plasma H(e) is strongly associated with early-onset familial coronary artery disease.
  • A significant proportion of early familial CAD is likely attributable to genetic factors influencing H(e) production.
  • Targeting hyperhomocysteinemia may be a strategy for managing genetic risk in early CAD.

Related Concept Videos